How Does CAR-T Cell Therapy Work, Step by Step? (2026 Update)

CAR-T cell therapy proceeds through T-cell collection, manufacturing, preconditioning chemotherapy, cell infusion, and an observation admission; while the infusion itself is a single event, the entire process from collection to observation often takes two months or more.

Key Summary

• CAR-T is a cell therapy in which T cells taken from the patient's own body are engineered with an artificial receptor that recognizes cancer cells and then reinfused; it is classified as a genetically modified cell therapy (National Cancer Center Korea).
• It is used for certain relapsed or refractory blood cancers, including B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma, while use in solid tumors is still at the research stage.
• Manufacturing the cells usually takes several weeks, and the two hallmark side effects — cytokine release syndrome (CRS) and neurologic toxicity (ICANS) — typically appear anywhere from a few days to two weeks after infusion.
• The treatment is performed only at designated hospitals with intensive-care capability, and the full process from collection through observation often requires a stay of two months or more.

What Specific Steps Does CAR-T Treatment Involve?

1. The treatment proceeds through five stages. Stage 1 is T-cell collection, a procedure in which blood is circulated through a machine that filters out only the T cells; it takes a few hours and requires no anesthesia. Stage 2 sends the collected cells to a manufacturing facility, where a gene for an artificial receptor that targets a cancer cell marker (for example, CD19 in B-cell lymphoma or BCMA in multiple myeloma) is inserted and the cells are expanded — a process that usually takes several weeks.
2. During this manufacturing period, patients often receive bridging treatment to keep the disease from progressing. Stage 3 is lymphodepleting chemotherapy, given a few days before infusion once the cells are ready, which clears space for the new CAR-T cells to engraft.
3. Stage 4 is the intravenous infusion of the CAR-T cells; the infusion itself is brief and, as a rule, given only once. Stage 5 is the observation admission for monitoring side effects — patients are typically hospitalized for around two weeks and afterward must stay near the hospital for a further period, attending frequent outpatient visits.

Who Is It For, and When Is It Considered?

• CAR-T is not a first-line treatment given at initial diagnosis; rather, it is considered for certain blood cancers that have already received standard treatment but relapsed or failed to respond. Typical examples include B-cell lymphomas such as relapsed/refractory diffuse large B-cell lymphoma, acute lymphoblastic leukemia in children and young adults, and multiple myeloma after multiple prior lines of therapy.
• Eligibility is determined by the type of cancer, the type and number of prior treatments, overall performance status, heart/lung/kidney function, presence of active infection, and involvement of the central nervous system; the decision of whether CAR-T or hematopoietic stem cell transplant should come first is also made jointly.
• Because CAR-T for solid tumors remains at the research stage, at this point the discussion is limited to checking whether an eligible clinical trial is available.

What Are the Side Effects and Recovery Timeline?

• The most important side effects are cytokine release syndrome and neurologic toxicity. Cytokine release syndrome presents as high fever, chills, low blood pressure, and low oxygen levels; it can range from mild fever to a severity requiring intensive care. Neurologic toxicity appears as slurred speech or confusion, and is often first noticed by a caregiver rather than the patient.
• In addition, low blood counts can persist for an extended period, and immunoglobulin levels may drop, leaving patients vulnerable to infection for some time — this may call for prophylactic antibiotics, immunoglobulin replacement, and adjusted vaccination schedules. Patients are also advised to avoid driving for a set period after infusion.
• Over the longer term, regular blood tests and imaging are used to check for relapse. Because of this level of management complexity, CAR-T is performed only at hospitals equipped with intensive-care capability and a dedicated response system.

FAQ — Is Only One Infusion Needed?

As a rule, the infusion itself is given only once. However, because the preceding collection, manufacturing, and preconditioning steps, along with the follow-up observation period afterward, all take considerable time, the overall process is not a single injection but a multi-stage journey. Cell manufacturing usually takes several weeks, and combining collection through observation, patients often need to plan for a stay of two months or more; the exact duration depends on the hospital's schedule and manufacturing turnaround.

FAQ — Which Should Come First, Transplant or CAR-T?

The order depends on the type of cancer, prior treatment history, availability of a donor, and the current state of the disease. The NCCN patient guidelines describe where CAR-T fits relative to prior treatment history for the relevant blood cancers, and a review weighing both treatment options can be summarized and provided in the form of a written opinion.

Sources and Notes

• This article was prepared based on materials from the National Cancer Center Korea, the NCCN patient guidelines, and the Korea Health Industry Development Institute (medicalkorea.or.kr).
• This content is intended for general medical information purposes only; actual diagnosis, treatment methods, and outcomes may vary depending on the individual's condition. Accurate diagnosis and treatment decisions should always be made in consultation with a physician.